**Biased ligands of class A G protein-coupled receptors over the past 20 years**

Jixia Wang a,b, Fangfang Xu b, Yanfang Liu a,b, Han Zhou a,b, Wenjie Yuan b, Fan Liu a ,Ye Fang a,\*, Xinmiao Liang a,b,\*

a Key Laboratory of Phytochemistry and Natural Medicines, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China

b Jiangxi Provincial Key Laboratory for Pharmacodynamic Material Basis of Traditional Chinese Medicine, Ganjiang Chinese Medicine Innovation Center, Nanchang 330000, China

\* Corresponding authors: Ye Fang, Xinmiao Liang

Tel.: +86 411 84379519; fax: +86 411 84379539.

E-mail addresses: fangye@dicp.ac.cn, liangxm@dicp.ac.cn

**Table S1** Class A GPCR biased ligands.

| No. | Receptor family | Target | Name in main text | Ligand | Biased signaling | Reference |
| --- | --- | --- | --- | --- | --- | --- |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | compound 1 | G-protein | [1] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | compound 2 | G-protein | [1] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | compound 4 | G-protein | [1] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | NLX-101 (F15599) | pERK1/2 over β-arrestin recruitment or Ca2+ mobilization | [2, 3] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | NLX-112 (befiradol) | pERK1/2 over β-arrestin recruitment or Ca2+ mobilization | [4, 5] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | NLX-260 (Compound 44) | pERK1/2 over cAMP inhibition, β-arrestin recruitment and Ca2+ mobilization | [3] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | NLX-249 (Compound 56) | β-arrestin recruitment over pERK1/2, cAMP inhibition and Ca2+ mobilization | [3] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | compound 14 | pERK1/2 over cAMP inhibition | [6] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | NLX-204 (compound 17) | pERK1/2 over cAMP inhibition, β-arrestin recruitment and Ca2+ mobilization | [6] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | compound 27 | pERK1/2 over cAMP inhibition or β-arrestin recruitment | [6] |
|  | 5-Hydroxytryptamine | 5HT1A | 5-HT1A | 8-Oh-DPAT | β-arrestin | [6] |
|  | 5-Hydroxytryptamine | 5HT1B | / | 3-T1AM | cAMP inhibition over PLC activation | [7] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 25H-NBF | β-arrestin | [8] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 25H-NBMD | β-arrestin | [8] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 25H-NBOH | β-arrestin | [8] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 25H-NBOMe | β-arrestin | [8] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 4a | β-arrestin | [9] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 4b | β-arrestin | [9] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 6e | β-arrestin | [9] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | 6f | β-arrestin | [9] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | altanserin | Gi1 over Gq | [10] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | pimavanserin | Gi1 over Gq | [10] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | *(R)*-69 | Gq-protein | [11] |
|  | 5-Hydroxytryptamine | 5HT2A | 5-HT2A | *(R)*-70 | Gq-protein | [11] |
|  | 5-Hydroxytryptamine | 5HT2B | 5-HT2B | ergotamine | β-arrestin | [12] |
|  | 5-Hydroxytryptamine | 5HT2B | 5-HT2B | lysergic acid diethylamide | β-arrestin | [12] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | (*R*)-asimilobine | Gq-protein | [13] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | 11b | Gq-protein | [14] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | 11f | Gq-protein | [14] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | compound (+)-7e | Gq-protein | [15] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | compound (+)-15a | Gq-protein | [16] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | compound (+)-19 | Gq-protein | [16] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | aripiprazole | G-protein | [17] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | lorcaserin | G-protein | [17] |
|  | 5-Hydroxytryptamine | 5HT2C | 5-HT2C | MBP | G-protein | [17] |
|  | 5-Hydroxytryptamine | 5HT4R | / | RS 67333 | Gs over Gq | [18] |
|  | 5-Hydroxytryptamine | 5HT4R | / | prucalopride | Gs over Gq | [18] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 1g | β-arrestin | [19] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 2b | G-protein | [20] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | serodolin | β-arrestin | [21] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 3c | G-protein | [22] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 3f | G-protein | [22] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 3i | G-protein | [22] |
|  | 5-Hydroxytryptamine | 5HT7R | 5-HT7 | 3p | G-protein | [22] |
|  | Acetylcholine (muscarinic) | ACM1 | M1 | TBPB | G-protein | [23] |
|  | Acetylcholine (muscarinic) | ACM1 | M1 | AC-260584 | G-protein | [23] |
|  | Acetylcholine (muscarinic) | ACM1 | M1 | VU0357017 | G-protein | [24] |
|  | Acetylcholine (muscarinic) | ACM1 | M1 | VU0364572 | G-protein | [24] |
|  | Acetylcholine (muscarinic) | ACM2 | M2 | Iper-6-naph | Gi-protein | [25] |
|  | Acetylcholine (muscarinic) | ACM2 | M2 | Iper-6-phth | Gi-protein | [25] |
|  | Acetylcholine (muscarinic) | ACM2 | M2 | McN-A-343 | G15 over Gi | [26] |
|  | Acetylcholine (muscarinic) | ACM2 | M2 | 6A | Gi over Gq | [27] |
|  | Acetylcholine (muscarinic) | ACM2 | M2 | 7A | Gi over Gq | [27] |
|  | Acetylcholine (muscarinic) | ACM3 | M3 | PD 102807 | β-arrestin | [28] |
|  | Acetylcholine (muscarinic) | ACM4 | M4 | xanomeline | Gi2 over pERK1/2 and Ca2+ mobilization | [29] |
|  | Acetylcholine (muscarinic) | ACM4 | M4 | 6A | Gi over Gq | [27] |
|  | Acetylcholine (muscarinic) | ACM4 | M4 | 7A | Gi over Gq | [27] |
|  | Acetylcholine (muscarinic) | ACM5 | M5 | 7A | Gi over Gq | [27] |
|  | Adrenoceptors | ADA1A | α1A | oxymetazoline | extracellular acidification rate over Ca2+ mobilization and cAMP production | [30] |
|  | Adrenoceptors | ADA1A | α1A | phenylephrine | extracellular acidification rate over Ca2+ mobilization and cAMP production | [30] |
|  | Adrenoceptors | ADA1A | α1A | cirazoline | cAMP production and Ca2+ mobilization | [30] |
|  | Adrenoceptors | ADA1A | α1A | A61603 | cAMP production and Ca2+ mobilization | [30] |
|  | Adrenoceptors | ADA2C | α2C | clonidine | β-arrestin recruitment over cAMP inhibition, Ca2+ mobilization or receptor internalization | [31] |
|  | Adrenoceptors | ADA2C | α2C | UK14,304 (brimonidine) | β-arrestin recruitment over cAMP inhibition, Ca2+ mobilization or receptor internalization | [31] |
|  | Adrenoceptors | ADA2C | α2C | guanabenz | β-arrestin recruitment over cAMP inhibition, Ca2+ mobilization or receptor internalization | [31] |
|  | Adrenoceptors | ADA2C | α2C | moxonidine | β-arrestin recruitment over cAMP inhibition, Ca2+ mobilization or receptor internalization | [31] |
|  | Adrenoceptors | ADA2C | α2C | phenylephrine | β-arrestin recruitment over cAMP inhibition, Ca2+ mobilization or receptor internalization | [31] |
|  | Adrenoceptors | ADRB1 | β1 | metoprolol | β-arrestin | [32] |
|  | Adrenoceptors | ADRB1 | β1 | nebivolol | β-arrestin | [33] |
|  | Adrenoceptors | ADRB1 | β1 | bucindolol | β-arrestin | [34, 35] |
|  | Adrenoceptors | ADRB1 | β1 | alprenolol | β-arrestin | [36] |
|  | Adrenoceptors | ADRB1 | β1 | STD-101-D1 | G-protein | [37] |
|  | Adrenoceptors | ADRB1 | β1 | xamoterol | G-protein | [37, 38] |
|  | Adrenoceptors | ADRB2 | β2 | formoterol | β-arrestin | [39] |
|  | Adrenoceptors | ADRB2 | β2 | dichloroisoproterenol | β-arrestin | [39] |
|  | Adrenoceptors | ADRB2 | β2 | salmeterol | β-arrestin | [39] |
|  | Adrenoceptors | ADRB2 | β2 | pindolol | β-arrestin | [39] |
|  | Adrenoceptors | ADRB2 | β2 | isoetharine | β-arrestin | [40] |
|  | Adrenoceptors | ADRB2 | β2 | N-cyclopentylbutanephrine | β-arrestin | [40] |
|  | Adrenoceptors | ADRB2 | β2 | ethylnorepinephrine | β-arrestin | [40] |
|  | Adrenoceptors | ADRB2 | β2 | ICL3-9 | Gs-protein | [41] |
|  | Adrenoceptors | ADRB2 | β2 | ICL3-4 | β-arrestin | [41] |
|  | Adrenoceptors | ADRB2 | β2 | *(R,R)*-fenoterol | Gs over Gi | [42] |
|  | Adrenoceptors | ADRB2 | β2 | *(S,R)*-4'-methoxyfenoterol | Gs-protein | [43] |
|  | Adrenoceptors | ADRB2 | β2 | *(R,S')*-4'-methoxy-1-naphthyl-fenoterol | Gs-protein | [44] |
|  | Adrenoceptors | ADRB2 | β2 | *(S,S')*-4'-methoxy-1-naphthyl-fenoterol | Gs-protein | [44] |
|  | Adrenoceptors | ADRB2 | β2 | ICL1-9 | β-arrestin | [45] |
|  | Adrenoceptors | ADRB2 | β2 | carmoterol | β-arrestin | [46] |
|  | Adrenoceptors | ADRB2 | β2 | L2 | β-arrestin | [47] |
|  | Adrenoceptors | ADRB2 | β2 | L4 | β-arrestin | [47] |
|  | Adrenoceptors | ADRB2 | β2 | L12 | β-arrestin | [47] |
|  | Adrenoceptors | ADRB2 | β2 | ractopamine | Gs-protein | [48] |
|  | Adrenoceptors | ADRB2 | β2 | dobutamine | Gs-protein | [48] |
|  | Adrenoceptors | ADRB2 | β2 | higenamine | Gs-protein | [48] |
|  | Adrenoceptors | ADRB2 | β2 | C1-S | Gs-protein | [49] |
|  | Adrenoceptors | ADRB2 | β2 | carvedilol | β-arrestin | [50] |
|  | Adrenoceptors | ADRB2 | β2 | propranolol | β-arrestin | [51] |
|  | Adrenoceptors | ADRB2 | β2 | ICI-118,551 | β-arrestin | [51] |
|  | Dopamine | DRD1 | D1 | apomorphine | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | SKF83959 | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | SKF38393 | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | SKF82957 | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | SKF77434 | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | SKF75670 | G-protein | [52] |
|  | Dopamine | DRD1 | D1 | compound 10 | G-protein | [53] |
|  | Dopamine | DRD1 | D1 | compound 35 | Gs-protein | [53] |
|  | Dopamine | DRD1 | D1 | PF-06649751 (CVL-751, tavapandon) | G-protein | [54] |
|  | Dopamine | DRD1 | D1 | PF-8294 | Gs-protein | [55] |
|  | Dopamine | DRD1 | D1 | PF-6142 | Gs-protein | [55] |
|  | Dopamine | DRD1 | D1 | PF-1119 | Gs-protein | [55] |
|  | Dopamine | DRD1 | D1 | PF-2334 | Gs-protein | [55] |
|  | Dopamine | DRD2 | D2 | UNC9975 | β-arrestin | [56] |
|  | Dopamine | DRD2 | D2 | UNC0006 | β-arrestin | [56] |
|  | Dopamine | DRD2 | D2 | UNC9994 | β-arrestin | [56] |
|  | Dopamine | DRD2 | D2 | compound 7 | β-arrestin | [57] |
|  | Dopamine | DRD2 | D2 | MLS1547 | G-protein | [58] |
|  | Dopamine | DRD2 | D2 | *(S)*-1 | Go over Gi | [59] |
|  | Dopamine | DRD2 | D2 | *(S)*-2 | Go over Gi | [59] |
|  | Dopamine | DRD2 | D2 | *(R)*-4 | β-arrestin | [59] |
|  | Dopamine | DRD2 | D2 | compound 1 | G-protein | [60] |
|  | Dopamine | DRD2 | D2 | benzoxazinone 9d | β-arrestin | [61] |
|  | Dopamine | DRD2 | D2 | 13b | β-arrestin | [62] |
|  | Dopamine | DRD2 | D2 | pramipexole | β-arrestin | [62] |
|  | Dopamine | DRD2 | D2 | quinpirole | β-arrestin | [62] |
|  | Dopamine | DRD2 | D2 | ropinirole | β-arrestin | [62] |
|  | Dopamine | DRD2 | D2 | 16c | G-protein | [63] |
|  | Dopamine | DRD2 | D2 | 11 | Go-protein | [64] |
|  | Dopamine | DRD2 | D2 | 19 | Go-protein | [64] |
|  | Dopamine | DRD2 | D2 | compound 19 | G-protein | [65] |
|  | Dopamine | DRD2 | D2 | MS1768 | G-protein | [66] |
|  | Dopamine | DRD2 | D2 | 36 | G-protein | [66] |
|  | Dopamine | DRD2 | D2 | 39 | G-protein | [66] |
|  | Dopamine | DRD2 | D2 | 40 | G-protein | [66] |
|  | Dopamine | DRD2 | D2 | 42 | G-protein | [66] |
|  | Dopamine | DRD2 | D2 | carbaldoxime 8b | Go-protein | [67] |
|  | Dopamine | DRD2 | D2 | aripiprazole | Go-protein | [67] |
|  | Dopamine | DRD2 | D2 | cariprazine | G-protein | [68] |
|  | Dopamine | DRD2 | D2 | 32 | G-protein | [68] |
|  | Dopamine | DRD2 | D2 | 10 | cAMP inhibition over pERK1/2 | [69] |
|  | Dopamine | DRD2 | D2 | 36 | cAMP inhibition over pERK1/2 | [70] |
|  | Dopamine | DRD3 | D3 | SK609 | G-protein | [71] |
|  | Dopamine | DRD3 | D3 | SK608 | G-protein | [71] |
|  | Histamine | HRH4 | H4 | JNJ7777120 | β-arrestin | [72, 73] |
|  | Histamine | HRH4 | H4 | 47 indolecarboxamides | β-arrestin | [74] |
|  | Histamine | HRH4 | H4 | VUF5228 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF10214 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF5223 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF10056 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF6002 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF11273 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF11012 | β-arrestin | [75] |
|  | Histamine | HRH4 | H4 | VUF5222 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | VUF10778 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | VUF10185 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | VUF10192 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | UR-PI376 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | VUF10306 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | VUF4656 | Gi-protein | [75] |
|  | Histamine | HRH4 | H4 | clozapine | Gi-protein | [75] |
|  | Trace amine | TAAR1 | TAAR1 | ZH8651 | Gs and Gq-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | ZH8659 | Gq-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | ZH8667 | Gs-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | SEP-363856 | Gs-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | β-phenylethylamine | Gs-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | 3-iodothyronamine | Gs-protein | [76] |
|  | Trace amine | TAAR1 | TAAR1 | cyclohexylamine | Gq-protein | [76] |
|  | Angiotensin | AGTR1 | TAAR1 | TRV120023 | β-arrestin | [77] |
|  | Angiotensin | AGTR1 | AT1R | TRV120027 | β-arrestin | [77-79] |
|  | Angiotensin | AGTR1 | AT1R | TRV120055 | Gq protein | [80] |
|  | Angiotensin | AGTR1 | AT1R | [Sar1, Ile4, Ile8]-angiotensin II | β-arrestin | [81, 82] |
|  | Angiotensin | AGTR1 | AT1R | Ang-(1-7) | β-arrestin | [83] |
|  | Angiotensin | AGTR1 | AT1R | SIII | G12-protein | [84] |
|  | Apelin | APJ | APJ | ML233 | β-arrestin | [85] |
|  | Apelin | APJ | APJ | compound 1 | G-protein | [86] |
|  | Apelin | APJ | APJ | compound 4 | G-protein | [86] |
|  | Apelin | APJ | APJ | compound 11 | G-protein | [86] |
|  | Apelin | APJ | APJ | compound 15 | G-protein | [86] |
|  | Apelin | APJ | APJ | 29 | Ca2+ mobilization over β-arrestin recruitment | [87] |
|  | Apelin | APJ | APJ | K16P | Gi-protein | [88] |
|  | Apelin | APJ | APJ | Apelin-36-L28A | G-protein | [89] |
|  | Apelin | APJ | APJ | Apelin-36-L28C(30kDa-PEG) | G-protein | [89] |
|  | Apelin | APJ | APJ | MM07 | G-protein | [90] |
|  | Apelin | APJ | APJ | CMF-019 | G-protein | [91] |
|  | Apelin | APJ | APJ | SBI-’569 | β-arrestin | [92] |
|  | Apelin | APJ | APJ | SBI-’681 | β-arrestin | [92] |
|  | Apelin | APJ | APJ | SBI-’547 | Gi-protein | [92] |
|  | Apelin | APJ | APJ | SBI-’612 | Gi-protein | [92] |
|  | Apelin | APJ | APJ | (-)-epicatechin | β-arrestin | [93] |
|  | Apelin | APJ | APJ | WN353 | G-protein | [94] |
|  | Apelin | APJ | APJ | WN561 | G-protein | [94] |
|  | Complement | C3AR | / | EP141 | G-protein | [95] |
|  | Complement | C5AR1 | C5aR1 | BM213 | G-protein | [96, 97] |
|  | Endothelin | EDNRA | ETA | ET-2 | G-protein | [98] |
|  | Endothelin | EDNRA | ETA | ET-3 | G-protein | [98] |
|  | Formylpeptide | FPR2 | / | F2Pal10 | G-protein | [99] |
|  | Ghrelin | GHSR | GHSR | YIL781 | G-protein | [100] |
|  | Ghrelin | GHSR | GHSR | Abb13d | G-protein | [100] |
|  | Ghrelin | GHSR | GHSR | N8279 (NCATS-SM8864) | Gq-protein | [101] |
|  | Melanocortin | MC4R | / | CJL-5-58 | G-protein | [102] |
|  | Melanocortin | MC4R | / | SHU9119 | pERK1/2 over cAMP production | [103] |
|  | Melanocortin | MC4R | / | MBP10 | pERK1/2 over cAMP production | [103] |
|  | Melanocortin | MC4R | / | BMS- 470539 | pERK1/2 over cAMP production | [104] |
|  | Melanocortin | MC4R | / | [D-Trp 8 ]-γMSH | pERK1/2 over cAMP production | [104] |
|  | Neuropeptide S | NPSR1 | NPSR | hNPS-(1-10) | Gq over Gs | [105] |
|  | Neuropeptide S | NPSR1 | NPSR | analog 4 (RTI-263, SerPheLysAsn-NH2) | Gq over Gs | [106] |
|  | Neuropeptide Y | NPY1R | / | G(34)-NPY | G-protein | [107] |
|  | Neurotensin | NTR1 | NTR1 | SBI-553 | β-arrestin | [108] |
|  | Neurotensin | NTR1 | NTR1 | ML314 | β-arrestin | [109] |
|  | Opioid | OPRD | DOR | mitragynine | Gi-protein | [110] |
|  | Opioid | OPRD | DOR | 7-hydroxymitragynine | Gi-protein | [110] |
|  | Opioid | OPRD | DOR | speciogynine | Gi-protein | [110] |
|  | Opioid | OPRD | DOR | paynantheine | Gi-protein | [110] |
|  | Opioid | OPRD | DOR | PN6047 | G-protein | [111] |
|  | Opioid | OPRD | DOR | TAN-67 | G-protein | [112] |
|  | Opioid | OPRD | DOR | TRV250 | Gi-protein | [113] |
|  | Opioid | OPRD | DOR | rubiscolin-5 | G-protein | [114] |
|  | Opioid | OPRD | DOR | rubiscolin-6 | G-protein | [114] |
|  | Opioid | OPRD | DOR | BMS 986187 | G-protein | [115] |
|  | Opioid | OPRD | DOR | UFP-512 | G-protein | [116] |
|  | Opioid | OPRD | DOR | BAM 18 | β-arrestin | [117] |
|  | Opioid | OPRD | DOR | BAM 12 | G-protein | [117] |
|  | Opioid | OPRK | KOR | mitragynine | Gi-protein | [110] |
|  | Opioid | OPRK | KOR | 7-hydroxymitragynine | Gi-protein | [110] |
|  | Opioid | OPRK | KOR | speciogynine | Gi-protein | [110] |
|  | Opioid | OPRK | KOR | paynantheine | Gi-protein | [110] |
|  | Opioid | OPRK | KOR | 6'-GNTI | G-protein | [118] |
|  | Opioid | OPRK | KOR | RB-64 | Gi-protein | [119] |
|  | Opioid | OPRK | KOR | triazole 1.1 | G-protein | [120, 121] |
|  | Opioid | OPRK | KOR | HS666 | G-protein | [122] |
|  | Opioid | OPRK | KOR | collybolide | Gi-protein | [123] |
|  | Opioid | OPRK | KOR | compound 2.1 | G-protein | [121] |
|  | Opioid | OPRK | KOR | noribogaine | G-protein | [124] |
|  | Opioid | OPRK | KOR | compound 81 | G-protein | [125] |
|  | Opioid | OPRK | KOR | LOR17 | G-protein | [126] |
|  | Opioid | OPRK | KOR | nalfurafine | G-protein | [127, 128] |
|  | Opioid | OPRK | KOR | WMS-X600 | β-arrestin | [127] |
|  | Opioid | OPRK | KOR | compound 2.3 | G-protein | [129] |
|  | Opioid | OPRK | KOR | U62066 | G-protein | [130] |
|  | Opioid | OPRK | KOR | ICI-199,441 | G-protein | [131] |
|  | Opioid | OPRK | KOR | etorphine | G-protein | [131] |
|  | Opioid | OPRK | KOR | levorphanol | G-protein | [131] |
|  | Opioid | OPRK | KOR | nalbuphine | β-arrestin | [131] |
|  | Opioid | OPRK | KOR | tifluadom | β-arrestin | [131] |
|  | Opioid | OPRM | MOR | PZM21 | Gi-protein | [132] |
|  | Opioid | OPRM | MOR | TRV130 (oliceridine) | Gi-protein | [133, 134] |
|  | Opioid | OPRM | MOR | SHR9352 | G-protein | [135] |
|  | Opioid | OPRM | MOR | TRV734 | Gi-protein | [136, 137] |
|  | Opioid | OPRM | MOR | buprenorphine | G-protein | [138] |
|  | Opioid | OPRM | MOR | C5 guano | G-protein | [139] |
|  | Opioid | OPRM | MOR | C6 guano | G-protein | [139] |
|  | Opioid | OPRM | MOR | SR-17018 | G-protein | [140] |
|  | Opioid | OPRM | MOR | SR-14968 | G-protein | [140, 141] |
|  | Opioid | OPRM | MOR | fentanyl | β-arrestin | [140] |
|  | Opioid | OPRM | MOR | SR-11501 | β-arrestin | [140] |
|  | Opioid | OPRM | MOR | SR-15098 | G-protein | [140] |
|  | Opioid | OPRM | MOR | SR-15099 | G-protein | [140] |
|  | Opioid | OPRM | MOR | LPM3480392 | Gi-protein | [142] |
|  | Opioid | OPRM | MOR | compound 44 | G-protein | [143] |
|  | Opioid | OPRM | MOR | NAP | G-protein | [144] |
|  | Opioid | OPRM | MOR | morphine | Gi-protein | [145] |
|  | Opioid | OPRM | MOR | mitragynine | Gi-protein | [146] |
|  | Opioid | OPRM | MOR | 7-hydroxymitragynine | Gi-protein | [146] |
|  | Opioid | OPRM | MOR | speciogynine | Gi-protein | [110] |
|  | Opioid | OPRM | MOR | paynantheine | Gi-protein | [110] |
|  | Opioid | OPRM | MOR | CYX-6 | G-protein | [147] |
|  | Opioid | OPRM | MOR | mitragynine pseudoindoxyl | Gi-protein | [148] |
|  | Opioid | OPRM | MOR | levorphanol | Gi-protein | [149] |
|  | Opioid | OPRM | MOR | herkinorin | G-protein | [150] |
|  | Opioid | OPRM | MOR | kurkinorin | G-protein | [151] |
|  | Opioid | OPRM | MOR | endomorphin-1 | G-protein | [152] |
|  | Opioid | OPRM | MOR | endomorphin-2 | G-protein | [152] |
|  | Opioid | OPRM | MOR | Met-Enkephalin-Rf | G-protein | [152] |
|  | Opioid | OPRM | MOR | loperamide | G-protein | [152] |
|  | Opioid | OPRM | MOR | a-neoendorphin | G-protein | [152] |
|  | Opioid | OPRM | MOR | corydine | Gi-protein | [153] |
|  | Opioid | OPRM | MOR | corydaline | Gi-protein | [153] |
|  | Opioid | OPRM | MOR | Dmt-c[D-Lys- Phe-Asp] NH2 (C33) | β-arrestin | [154] |
|  | Opioid | OPRM | MOR | Dmt-c[D-Lys-Phe-p-CF3-Phe-Asp]NH2 (F-81) | G-protein | [154] |
|  | Opioid | OPRM | MOR | Tyr-c[D-Lys-Phe-Tyr-Gly] (Compound 1) | G-protein | [155] |
|  | Opioid | OPRM | MOR | desmetramadol | G-protein | [156] |
|  | Opioid | OPRM | MOR | bilorphin | G-protein | [157] |
|  | Opioid | OPRM | MOR | carfentanil | β-arrestin | [158] |
|  | Opioid | OPRX | NOP | MCOPPB | G-protein | [159] |
|  | Opioid | OPRX | NOP | NNC 63-0532 | G-protein | [159] |
|  | Opioid | OPRX | NOP | buprenorphine | Gi-protein | [159] |
|  | Opioid | OPRX | NOP | RTI-819 | G-protein | [159] |
|  | Opioid | OPRX | NOP | RTI-856 | G-protein | [159] |
|  | Opioid | OPRX | NOP | Ro 65-6570 | G-protein | [160] |
|  | Opioid | OPRX | NOP | cebranopadol | G-protein | [161] |
|  | Opioid | OPRX | NOP | BPR1M97 | G-protein | [162] |
|  | Proteinase-activated | PAR2 | PAR2 | SLAAAA-amide | pERK1/2 over Ca2+ mobilization | [163] |
|  | Proteinase-activated | PAR2 | PAR2 | GB88 | Gi-protein, G12/13-protein and pERK1/2 over Gq-protein | [164] |
|  | Proteinase-activated | PAR2 | PAR2 | cathepsin S | Gs-protein | [165] |
|  | Relaxin family | RXFP1 | RXFP1 | ML290 | cGMP and cAMP accumulation over pERK1/2 | [166] |
|  | Relaxin family | RL3R1 | / | H2 Relaxin | activator protein (AP)-1 over pERK1/2 and cAMP inhibition | [167] |
|  | Tachykinin | NK1R | / | SP6-11 | Gq over Gs | [168] |
|  | Urotensin | UR2R | / | [Orn8]UII | G-protein | [169] |
|  | Urotensin | UR2R | / | [Orn5]URP | G-protein | [169] |
|  | Urotensin | UR2R | / | urantide | G-protein | [169] |
|  | Vasopressin/oxytocin | V2R | / | MCF14 | Gs-protein | [170] |
|  | Vasopressin/oxytocin | V2R | / | SR121463 | β-arrestin | [170] |
|  | Vasopressin/oxytocin | V2R | / | I8-arachnotocin | G-protein | [171] |
|  | Vasopressin/oxytocin | OXYR | OXYR | atosiban | Gi over Gq | [172] |
|  | Chemokine | CCR1 | / | CCL15 (28–92) | Gi-protein | [173] |
|  | Chemokine | CCR1 | / | CCL15 (29–92) | Gi-protein | [173] |
|  | Chemokine | CCR1 | / | CCL15 (30–92) | Gi-protein | [173] |
|  | Chemokine | CCR1 | / | CCL15 (31–92) | Gi-protein | [173] |
|  | Chemokine | CCR1 | / | CCL15 (26–92) | β-arrestin | [173] |
|  | Chemokine | CCR5 | / | J113863 | Gi over Goa and Ca2+ mobilization | [174] |
|  | Chemokine | CCR5 | / | 5P12-RANTES | Gi over Gq | [175] |
|  | Chemokine | CCR5 | / | 5P14-RANTES | Gi over Gq | [175] |
|  | Chemokine | CCR5 | / | 6P4-RANTES | Gq over Gi | [175] |
|  | Chemokine | CCR5 | / | PSC-RANTES | Gq over Gi | [175] |
|  | Chemokine | CXCR2 | / | CXCL1-3 | G-protein | [176] |
|  | Chemokine | CXCR2 | / | CXCL5-7 | G-protein | [176] |
|  | Chemokine | CXCR3 | / | CXCL9 | G-protein | [177] |
|  | Chemokine | CXCR3 | / | CXCL11 | β-arrestin | [178] |
|  | Chemokine | CXCR3 | / | VUF10661 | β-arrestin | [178] |
|  | Chemokine | CXCR3 | / | VUF11418 | G-protein | [178] |
|  | Chemokine | CXCR3 | / | FAUC1036 | β-arrestin | [179] |
|  | Chemokine | CXCR3 | / | FAUC1104 | G-protein | [179] |
|  | Chemokine | CXCR4 | / | ATI-2341 | Gi-protein | [180] |
|  | Free fatty acid | FFAR4 | FFA4 | eicosapentaenoic acid | Gs over Gi or Gq | [181] |
|  | Free fatty acid | FFAR4 | FFA4 | TUG891 | Gq over Gi | [181] |
|  | Free fatty acid | FFAR4 | FFA4 | compound 25 | β-arrestin | [182] |
|  | Free fatty acid | FFAR4 | FFA4 | compound 50 | β-arrestin | [182] |
|  | Lysophospholipid | S1PR1 | S1PR1 | HDL-bound S1P | MAPK and β-arrestin recruitment over cAMP inhibition | [183] |
|  | Lysophospholipid | S1PR1 | S1PR1 | BMS-986104 | G-protein | [184] |
|  | Lysophospholipid | S1PR3 | S1PR3 | ALESIA | G12-protein | [185] |
|  | Cannabinoid | CNR1 | CB1 | CP 55,940 | β-arrestin | [186] |
|  | Cannabinoid | CNR1 | CB1 | Δ9-tetrahydrocannabinol | β-arrestin | [186, 187] |
|  | Cannabinoid | CNR1 | CB1 | 2-arachidonoylglycerol | G-protein | [186] |
|  | Cannabinoid | CNR1 | CB1 | anandamide | G-protein | [186] |
|  | Cannabinoid | CNR1 | CB1 | ICAM-b | β-arrestin | [188] |
|  | Cannabinoid | CNR1 | CB1 | compound 7d | β-arrestin | [189] |
|  | Cannabinoid | CNR1 | CB1 | compound 8d | β-arrestin | [189] |
|  | Cannabinoid | CNR1 | CB1 | EG-018 | G-protein | [190] |
|  | Cannabinoid | CNR1 | CB1 | CB-02 | Gi-protein | [191] |
|  | Cannabinoid | CNR1 | CB1 | CB-05 | Gi-protein | [191] |
|  | Cannabinoid | CNR1 | CB1 | (+)-(R,S)-14 | Gi-protein | [192] |
|  | Cannabinoid | CNR2 | CB2 | UR144 | β-arrestin | [193] |
|  | Cannabinoid | CNR2 | CB2 | STS135 | β-arrestin | [193] |
|  | Cannabinoid | CNR2 | CB2 | AM-1248 | β-arrestin | [193] |
|  | Cannabinoid | CNR2 | CB2 | 4-O-methylhonokiol | β-arrestin | [193] |
|  | Cannabinoid | CNR2 | CB2 | THC | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | JWH133 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | WIN-55212 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | KM233 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | HU308 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | AM1241 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | JWH015 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | MAM2201 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | AM2232 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | SRE601 | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | 2-arachidonoyl glycerol | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | Meth-anandamide | G-protein | [193] |
|  | Cannabinoid | CNR2 | CB2 | 14 | internalisation over cAMP and pERK1/2 | [194] |
|  | Cannabinoid | CNR2 | CB2 | 15 | internalisation over cAMP and pERK1/2 | [194] |
|  | Cannabinoid | CNR2 | CB2 | 7 | pERK1/2 over cAMP and internalisation | [194] |
|  | Prostanoid | PE2R2 | / | 18a | G-protein | [195] |
|  | Prostanoid | PE2R4 | / | PGE2 | Gs over Gi and β-arrestin | [196] |
|  | Prostanoid | PE2R4 | / | PGE1 alcohol | Gi1 and β-arrestin over Gs | [196] |
|  | Adenosine | AA1R | A1R | VCP746 | Gi-protein over pERK1/2 | [197] |
|  | Adenosine | AA1R | A1R | 6 | cAMP inhibition over Ca2+ mobilization | [198] |
|  | Adenosine | AA1R | A1R | 16 | Ca2+ mobilization over cAMP inhibition | [198] |
|  | Adenosine | AA1R | A1R | capadenoson | cAMP inhibition over pERK1/2 and Ca2+ mobilization | [199] |
|  | Adenosine | AA1R | A1R | 8h | cAMP accumulation over pERK1/2 | [200] |
|  | Adenosine | AA1R | A1R | LUF5589 | G-protein | [201] |
|  | Adenosine | AA1R | A1R | BnOCPA | Gob-protein | [202] |
|  | Bile acid | GPBAR | GPBAR | R399 | β-arrestin | [203] |
|  | Bile acid | GPBAR | GPBAR | INT-777 | Gs-protein | [203] |
|  | Hydroxycarboxylic acid | HCAR2 | HCAR2 | compound 9n | Gi-protein | [204] |
|  | Hydroxycarboxylic acid | HCAR2 | HCAR2 | MK-0354 | G-protein | [205, 206] |
|  | Hydroxycarboxylic acid | HCAR2 | HCAR2 | MK6892 | G-protein | [207] |
|  | Hydroxycarboxylic acid | HCAR2 | HCAR2 | monomethyl fumarate | G-protein | [207] |
|  | Class A Orphans | GPR84 | / | DL-175 | G-protein | [208] |
|  | Class A Orphans | GPR84 | / | OX04528 | G-protein | [209] |
|  | Class A Orphans | GPR84 | / | OX04529 | G-protein | [209] |
|  | Class A Orphans | MRGX2 | / | AG-30/5C | G-protein | [210] |
|  | Class A Orphans | MRGX2 | / | icatibant | G-protein | [210] |

**References**

1. Stroth N, Niso M, Colabufo NA, Perrone R, Svenningsson P, Lacivita E*, et al.* Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of beta-arrestin-2. **Bioorganic & Medicinal Chemistry** **2015**, 23(15)**:** 4824-4830. doi: 10.1016/j.bmc.2015.05.042

2. Newman-Tancredi A, Martel JC, Assie MB, Buritova J, Lauressergues E, Cosi C*, et al.* Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist. **British Journal of Pharmacology** **2009**, 156(2)**:** 338-353. doi: 10.1111/j.1476-5381.2008.00001.x

3. Sniecikowska J, Gluch-Lutwin M, Bucki A, Wieckowska A, Siwek A, Jastrzebska-Wiesek M*, et al.* Discovery of novel pERK1/2- or β-arrestin-preferring 5-HT1A receptor-biased agonists: diversified therapeutic-like versus side effect profile. **Journal of Medicinal Chemistry** **2020**, 63(19)**:** 10946-10971. doi: 10.1021/acs.jmedchem.0c00814

4. Newman-Tancredi A, Martel JC, Cosi C, Heusler P, Lestienne F, Varney MA*, et al.* Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT(1A) receptor agonist. **Journal of Pharmacy and Pharmacology** **2017**, 69(9)**:** 1178-1190. doi: 10.1111/jphp.12762

5. Newman-Tancredi A, Depoortere RY, Kleven MS, Kolaczkowski M, Zimmer L. Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders. **Pharmacology & Therapeutics** **2022**, 229**:** 107937. doi: 10.1016/j.pharmthera.2021.107937

6. Sniecikowska J, Gluch-Lutwin M, Bucki A, Wieckowska A, Siwek A, Jastrzebska-Wiesek M*, et al.* Novel aryloxyethyl derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the extracellular regulated kinases 1/2 (ERK1/2) phosphorylation-preferring serotonin 5-HT1A receptor-biased agonists with robust antidepressant-like activity. **Journal of Medicinal Chemistry** **2019**, 62(5)**:** 2750-2771. doi: 10.1021/acs.jmedchem.9b00062

7. Braunig J, Dinter J, Hofig CS, Paisdzior S, Szczepek M, Scheerer P*, et al.* The trace amine-associated receptor 1 agonist 3-Iodothyronamine induces biased signaling at the serotonin 1b Receptor. **Frontiers in Pharmacology** **2018**, 9**:** 222. doi: 10.3389/fphar.2018.00222

8. Pottie E, Dedecker P, Stove CP. Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of β-arrestin 2 and miniGαq bioassays. **Biochemical Pharmacology** **2020**, 182**:** 114251. doi: 10.1016/j.bcp.2020.114251

9. Poulie CBM, Pottie E, Simon IA, Harpsoe K, D'Andrea L, Komarov IV*, et al.* Discovery of beta-arrestin-biased 25CN-NBOH-derived 5-HT(2A) receptor agonists. **Journal of Medicinal Chemistry** **2022**, 65(18)**:** 12031-12043. doi: 10.1021/acs.jmedchem.2c00702

10. Muneta-Arrate I, Miranda-Azpiazu P, Horrillo I, Diez-Alarcia R, Meana JJ. Ligand bias and inverse agonism on 5-HT(2A) receptor-mediated modulation of G protein activity in post-mortem human brain. **British Journal of Pharmacology** **2024:** 1–16. doi: 10.1111/bph.16368

11. Kaplan AL, Confair DN, Kim K, Barros-Alvarez X, Rodriguiz RM, Yang Y*, et al.* Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. **Nature** **2022**, 610(7932)**:** 582-591. doi: 10.1038/s41586-022-05258-z

12. Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E*, et al.* Structural features for functional selectivity at serotonin receptors. **Science** **2013**, 340(6132)**:** 615-619. doi: 10.1126/science.1232808

13. Zhang B, Zhao S, Yang D, Wu Y, Xin Y, Cao H*, et al.* A novel G protein-biased and subtype-selective agonist for a G protein-coupled receptor discovered from screening herbal extracts. **Acs Central Science** **2020**, 6(2)**:** 213-225. doi: 10.1021/acscentsci.9b01125

14. Mao Q, Zhang B, Tian S, Qin W, Chen J, Huang X-P*, et al.* Structural optimizations and bioevaluation of N-H aporphine analogues as Gq-biased and selective serotonin 5-HT2C receptor agonists. **Bioorganic Chemistry** **2022**, 123**:** 105795. doi: 10.1016/j.bioorg.2022.105795

15. Cheng J, McCorvy JD, Giguere PM, Zhu H, Kenakin T, Roth BL*, et al.* Design and discovery of functionally selective serotonin 2C (5-HT2C) receptor agonists. **Journal of Medicinal Chemistry** **2016**, 59(21)**:** 9866-9880. doi: 10.1021/acs.jmedchem.6b01194

16. Zhang G, Cheng J, McCorvy JD, Lorello PJ, Caldarone BJ, Roth BL*, et al.* Discovery of N-substituted (2-Phenylcyclopropyl)methylamines as functionally selective serotonin 2C receptor agonists for potential use as antipsychotic medications. **Journal of Medicinal Chemistry** **2017**, 60(14)**:** 6273-6288. doi: 10.1021/acs.jmedchem.7b00584

17. Felsing DE, Canal CE, Booth RG. Ligand-directed serotonin 5-HT(2C) receptor desensitization and sensitization. **European Journal of Pharmacology** **2019**, 848**:** 131-139. doi: 10.1016/j.ejphar.2019.01.037

18. Gaven F, Pellissier LP, Queffeulou E, Cochet M, Bockaert J, Dumuis A*, et al.* Pharmacological profile of engineered 5-HT(4) receptors and identification of 5-HT(4) receptor-biased ligands. **Brain Research** **2013**, 1511**:** 65-72. doi: 10.1016/j.brainres.2012.11.005

19. Kim Y, Kim H, Lee J, Lee JK, Min SJ, Seong J*, et al.* Discovery of β-arrestin biased ligands of 5-HT7R. **Journal of Medicinal Chemistry** **2018**, 61(16)**:** 7218-7233. doi: 10.1021/acs.jmedchem.8b00642

20. Lee J, Kwag R, Lee S, Kim D, Woo J, Cho Y*, et al.* Discovery of G protein-biased ligands against 5-HT7R. **Journal of Medicinal Chemistry** **2021**, 64(11)**:** 7453-7467. doi: 10.1021/acs.jmedchem.1c00110

21. El Khamlichi C, Reverchon F, Hervouet-Coste N, Robin E, Chopin N, Deau E*, et al.* Serodolin, a β-arrestin-biased ligand of 5-HT7 receptor, attenuates pain-related behaviors. **Proceedings of the National Academy of Sciences of the United States of America** **2022**, 119(21)**:** e2118847119. doi: 10.1073/pnas.2118847119

22. Kim D, Lee J, Kwag R, Kim H, Oh H, Moon B*, et al.* N‐(Biphenyl‐3‐ylmethyl)ethanamines as G protein‐biased agonists of 5‐HT7R. **Bulletin of the Korean Chemical Society** **2021**, 43(1)**:** 73-77. doi: 10.1002/bkcs.12427

23. Davis AA, Heilman CJ, Brady AE, Miller NR, Fuerstenau-Sharp M, Hanson BJ*, et al.* Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation. **ACS Chemical Neuroscience** **2010**, 1(8)**:** 542-551. doi: 10.1021/cn100011e

24. Digby GJ, Noetzel MJ, Bubser M, Utley TJ, Walker AG, Byun NE*, et al.* Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. **Journal of Neuroscience** **2012**, 32(25)**:** 8532-8544. doi: 10.1523/jneurosci.0337-12.2012

25. Bock A, Merten N, Schrage R, Dallanoce C, Batz J, Klockner J*, et al.* The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling. **Nature Communications** **2012**, 3**:** 1044. doi: 10.1038/ncomms2028

26. Griffin MT, Figueroa KW, Liller S, Ehlert FJ. Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15. **The Journal of Pharmacology and Experimental Therapeutics** **2007**, 321(3)**:** 1193-1207. doi: 10.1124/jpet.107.120857

27. Randakova A, Nelic D, Ungerova D, Nwokoye P, Su Q, Dolezal V*, et al.* Novel M2 -selective, Gi -biased agonists of muscarinic acetylcholine receptors. **British Journal of Pharmacology** **2020**, 177(9)**:** 2073-2089. doi: 10.1111/bph.14970

28. Tompkins E, Mimic B, Cuevas-Mora K, Schorsch H, Shah SD, Deshpande DA*, et al.* PD 102807 induces M3 mAChR-dependent GRK-/arrestin-biased signaling in airway smooth muscle cells. **American Journal of Respiratory Cell and Molecular Biology** **2022**, 67(5)**:** 550-561. doi: 10.1165/rcmb.2021-0320OC

29. McDonald JK, van der Westhuizen ET, Pham V, Thompson G, Felder CC, Paul SM*, et al.* Biased profile of xanomeline at the recombinant human M(4) muscarinic acetylcholine receptor. **Acs Chemical Neuroscience** **2022**, 13(8)**:** 1206-1218. doi: 10.1021/acschemneuro.1c00827

30. Evans BA, Broxton N, Merlin J, Sato M, Hutchinson DS, Christopoulos A*, et al.* Quantification of functional selectivity at the human alpha(1A)-adrenoceptor. **Molecular Pharmacology** **2011**, 79(2)**:** 298-307. doi: 10.1124/mol.110.067454

31. Kurko D, Kapui Z, Nagy J, Lendvai B, Kolok S. Analysis of functional selectivity through G protein-dependent and -independent signaling pathways at the adrenergic alpha(2C) receptor. **Brain Research Bulletin** **2014**, 107**:** 89-101. doi: 10.1016/j.brainresbull.2014.07.005

32. Nakaya M, Chikura S, Watari K, Mizuno N, Mochinaga K, Mangmool S*, et al.* Induction of cardiac fibrosis by beta-blocker in G protein-independent and G protein-coupled receptor kinase 5/beta-arrestin2-dependent Signaling pathways. **Journal of Biological Chemistry** **2012**, 287(42)**:** 35669-35677. doi: 10.1074/jbc.M112.357871

33. Erickson CE, Gul R, Blessing CP, Nguyen J, Liu T, Pulakat L*, et al.* The β-blocker Nebivolol Is a GRK/β-arrestin Biased Agonist. **PLoS One** **2013**, 8(8)**:** e71980. doi: 10.1371/journal.pone.0071980

34. Kopra K, Kainulainen M, Mikkonen P, Rozwandowicz-Jansen A, Hanninen P, Harma H. Multiparametric homogeneous method for identification of ligand binding to G protein-coupled receptors: receptor-ligand binding and beta-arrestin assay. **Analytical Chemistry** **2013**, 85(4)**:** 2276-2281. doi: 10.1021/ac303215r

35. Galandrin S, Oligny-Longpre G, Bonin H, Ogawa K, Gales C, Bouvier M. Conformational rearrangements and signaling cascades involved in ligand-biased mitogen-activated protein kinase signaling through the β1-adrenergic receptor. **Molecular Pharmacology** **2008**, 74(1)**:** 162-172. doi: 10.1124/mol.107.043893

36. Kim I-M, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD*, et al.* β-Blockers alprenolol and carvedilol stimulate β-arrestin-mediated EGFR transactivation. **Proceedings of the National Academy of Sciences of the United States of America** **2008**, 105(38)**:** 14555-14560. doi: 10.1073/pnas.0804745105

37. Yi B, Jahangir A, Evans AK, Briggs D, Ravina K, Ernest J*, et al.* Discovery of novel brain permeable and G protein-biased beta-1 adrenergic receptor partial agonists for the treatment of neurocognitive disorders. **PLoS One** **2017**, 12(7)**:** e0180319. doi: 10.1371/journal.pone.0180319

38. Ardestani PM, Evans AK, Yi B, Nguyen T, Coutellier L, Shamloo M. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. **Neuropharmacology** **2017**, 116**:** 371-386. doi: 10.1016/j.neuropharm.2017.01.010

39. Rajagopal S, Ahn S, Rominger DH, Gowen-MacDonald W, Lam CM, Dewire SM*, et al.* Quantifying ligand bias at seven-transmembrane receptors. **Molecular Pharmacology** **2011**, 80(3)**:** 367-377. doi: 10.1124/mol.111.072801

40. Drake MT, Violin JD, Whalen EJ, Wisler JW, Shenoy SK, Lefkowitz RJ. beta-arrestin-biased agonism at the beta2-adrenergic receptor. **The Journal of Biological Chemistry** **2008**, 283(9)**:** 5669-5676. doi: 10.1074/jbc.M708118200

41. Carr R, 3rd, Du Y, Quoyer J, Panettieri RA, Jr., Janz JM, Bouvier M*, et al.* Development and characterization of pepducins as Gs-biased allosteric agonists. **The Journal of Biological Chemistry** **2014**, 289(52)**:** 35668-35684. doi: 10.1074/jbc.M114.618819

42. Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW*, et al.* Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes. **Molecular Pharmacology** **2009**, 75(1)**:** 158-165. doi: 10.1124/mol.108.051078

43. Littmann T, Gottle M, Reinartz MT, Kalble S, Wainer IW, Ozawa T*, et al.* Recruitment of beta-arrestin 1 and 2 to the beta2-adrenoceptor: analysis of 65 ligands. **The Journal of Pharmacology and Experimental Therapeutics** **2015**, 355(2)**:** 183-190. doi: 10.1124/jpet.115.227959

44. Reinartz MT, Kalble S, Littmann T, Ozawa T, Dove S, Kaever V*, et al.* Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the beta2-adrenoceptor. **Naunyn-Schmiedeberg's Archives of Pharmacology** **2015**, 388(1)**:** 51-65. doi: 10.1007/s00210-014-1054-5

45. Carr R, III, Schilling J, Song J, Carter RL, Du Y, Yoo SM*, et al.* β-arrestin-biased signaling through the β2-adrenergic receptor promotes cardiomyocyte contraction. **Proceedings of the National Academy of Sciences of the United States of America** **2016**, 113(28)**:** E4107-E4116. doi: 10.1073/pnas.1606267113d

46. Nivedha AK, Tautermann CS, Bhattacharya S, Lee S, Casarosa P, Kollak I*, et al.* Identifying functional hotspot residues for biased ligand design in G-protein-coupled receptors. **Molecular Pharmacology** **2018**, 93(4)**:** 288-296. doi: 10.1124/mol.117.110395

47. Woo AY-H, Ge X-y, Pan L, Xing G, Mo Y-m, Xing R-j*, et al.* Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives. **Acta Pharmacologica Sinica** **2019**, 40(8)**:** 1095-1105. doi: 10.1038/s41401-018-0200-x

48. De Pascali F, Ippolito M, Wolfe E, Komolov KE, Hopfinger N, Lemenze D*, et al.* beta(2) -Adrenoceptor agonist profiling reveals biased signalling phenotypes for the beta(2) -adrenoceptor with possible implications for the treatment of asthma. **British Journal of Pharmacology** **2022**, 179(19)**:** 4692-4708. doi: 10.1111/bph.15900

49. Tokmakova A, Kim D, Goddard WA, 3rd, Liggett SB. Biased beta-agonists favoring Gs over beta-arrestin for individualized treatment of obstructive lung disease. **Journal of Personalized Medicine** **2022**, 12(3). doi: 10.3390/jpm12030331

50. Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S*, et al.* A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. **Proceedings of the National Academy of Sciences of the United States of America** **2007**, 104(42)**:** 16657-16662. doi: 10.1073/pnas.0707936104

51. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M*, et al.* β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. **Proceedings of the National Academy of Sciences of the United States of America** **2003**, 100(20)**:** 11406-11411. doi: 10.1073/pnas.1936664100

52. Conroy JL, Free RB, Sibley DR. Identification of G protein-biased agonists that fail to recruit beta-arrestin or promote internalization of the D1 dopamine receptor. **Acs Chemical Neuroscience** **2015**, 6(4)**:** 681-692. doi: 10.1021/acschemneuro.5b00020

53. Martini ML, Ray C, Yu X, Liu J, Pogorelov VM, Wetsel WC*, et al.* Designing functionally selective noncatechol dopamine D1 receptor agonists with potent in vivo antiparkinsonian activity. **Acs Chemical Neuroscience** **2019**, 10(9)**:** 4160-4182. doi: 10.1021/acschemneuro.9b00410

54. Jones-Tabah J, Mohammad H, Paulus EG, Clarke PBS, Hebert TE. The signaling and pharmacology of the dopamine D1 receptor. **Frontiers in Cellular Neuroscience** **2021**, 15**:** 806618. doi: 10.3389/fncel.2021.806618

55. Gray DL, Allen JA, Mente S, O'Connor RE, DeMarco GJ, Efremov I*, et al.* Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor. **Nature communications** **2018**, 9(1)**:** 674. doi: 10.1038/s41467-017-02776-7

56. Allen JA, Yost JM, Setola V, Chen X, Sassano MF, Chen M*, et al.* Discovery of β-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. **Proceedings of the National Academy of Sciences of the United States of America** **2011**, 108(45)**:** 18488-18493. doi: 10.1073/pnas.1104807108

57. McCorvy JD, Butler KV, Kelly B, Rechsteiner K, Karpiak J, Betz RM*, et al.* Structure-inspired design of β-arrestin-biased ligands for aminergic GPCRs. **Nature Chemical Biology** **2018**, 14(2)**:** 126-134. doi: 10.1038/nchembio.2527

58. Free RB, Chun LS, Moritz AE, Miller BN, Doyle TB, Conroy JL*, et al.* Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor. **Molecular Pharmacology** **2014**, 86(1)**:** 96-105. doi: 10.1124/mol.113.090563

59. Weichert D, Banerjee A, Hiller C, Kling RC, Hubner H, Gmeiner P. Molecular determinants of biased agonism at the dopamine D₂ receptor. **Journal of Medicinal Chemistry** **2015**, 58(6)**:** 2703-2717. doi: 10.1021/jm501889t

60. Chen X, McCorvy JD, Fischer MG, Butler KV, Shen Y, Roth BL*, et al.* Discovery of G protein-biased D2 dopamine receptor partial agonists. **Journal of Medicinal Chemistry** **2016**, 59(23)**:** 10601-10618. doi: 10.1021/acs.jmedchem.6b01208

61. Maennel B, Huebner H, Moeller D, Gmeiner P. β-Arrestin biased dopamine D2 receptor partial agonists: Synthesis and pharmacological evaluation. **Bioorganic & Medicinal Chemistry** **2017**, 25(20)**:** 5613-5628. doi: 10.1016/j.bmc.2017.08.037

62. Mannel B, Dengler D, Shonberg J, Hubner H, Moller D, Gmeiner P. Hydroxy-substituted heteroarylpiperazines: novel scaffolds for β-arrestin-biased D2R agonists. **Journal of Medicinal Chemistry** **2017**, 60(11)**:** 4693-4713. doi: 10.1021/acs.jmedchem.7b00363

63. Moller D, Banerjee A, Uzuneser TC, Skultety M, Huth T, Plouffe B*, et al.* Discovery of G protein-biased dopaminergics with a pyrazolo[1,5-a]pyridine substructure. **Journal of Medicinal Chemistry** **2017**, 60(7)**:** 2908-2929. doi: 10.1021/acs.jmedchem.6b01857

64. Bonifazi A, Yano H, Guerrero AM, Kumar V, Hoffman AF, Lupica CR*, et al.* Novel and potent dopamine D 2 receptor Go-protein biased agonists. **ACS Pharmacology & Translational Science** **2019**, 2(1)**:** 52-65. doi: 10.1021/acsptsci.8b00060

65. Bonifazi A, Yano H, Ellenberger MP, Muller L, Kumar V, Zou MF*, et al.* Novel bivalent ligands based on the sumanirole pharmacophore reveal dopamine D2 receptor (D2R) biased agonism **Journal of Medicinal Chemistry** **2017**, 60(7)**:** 2890-2907. doi: 10.1021/acs.jmedchem.6b01875

66. Shen Y, McCorvy JD, Martini ML, Rodriguiz RM, Pogorelov VM, Ward KM*, et al.* D 2 dopamine receptor G protein-biased partial agonists based on cariprazine. **Journal of Medicinal Chemistry** **2019**, 62(9)**:** 4755-4771. doi: 10.1021/acs.jmedchem.9b00508

67. Moller D, Kling RC, Skultety M, Leuner K, Hubner H, Gmeiner P. Functionally selective dopamine D(2), D(3) receptor partial agonists. **Journal of Medicinal Chemistry** **2014**, 57(11)**:** 4861-4875. doi: 10.1021/jm5004039

68. Shonberg J, Herenbrink CK, Lopez L, Christopoulos A, Scammells PJ, Capuano B*, et al.* A structure-activity analysis of biased agonism at the dopamine D2 receptor. **Journal of Medicinal Chemistry** **2013**, 56(22)**:** 9199-9221. doi: 10.1021/jm401318w

69. Reyes-Resina I, Samadi A, Navarro G, Saadeh HA, Khasawneh MA, Mestres J*, et al.* Identification of a tool compound to study the mechanisms of functional selectivity between D2 and D3 dopamine receptors. **ACS Omega** **2018**, 3(12)**:** 17368-17375. doi: 10.1021/acsomega.8b02509

70. Szabo M, Klein Herenbrink C, Christopoulos A, Lane JR, Capuano B. Structure-activity relationships of privileged structures lead to the discovery of novel biased ligands at the dopamine D(2) receptor. **Journal of Medicinal Chemistry** **2014**, 57(11)**:** 4924-4939. doi: 10.1021/jm500457x

71. Xu W, Wang X, Tocker AM, Huang P, Reith ME, Liu-Chen LY*, et al.* Functional characterization of a novel series of biased signaling dopamine D3 receptor agonists. **ACS Chemical Neuroscience** **2017**, 8(3)**:** 486-500. doi: 10.1021/acschemneuro.6b00221

72. Rosethorne EM, Charlton SJ. Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. **Molecular Pharmacology** **2011**, 79(4)**:** 749-757. doi: 10.1124/mol.110.068395

73. Suwa E, Yamaura K, Oda M, Namiki T, Ueno K. Histamine H4 receptor antagonist reduces dermal inflammation and pruritus in a hapten-induced experimental model. **European Journal of Pharmacology** **2011**, 667(1-3)**:** 383-388. doi: 10.1016/j.ejphar.2011.05.037

74. Nijmeijer S, Vischer HF, Sirci F, Schultes S, Engelhardt H, de Graaf C*, et al.* Detailed analysis of biased histamine H4 receptor signalling by JNJ 7777120 analogues. **British Journal of Pharmacology** **2013**, 170(1)**:** 78-88. doi: 10.1111/bph.12117

75. Nijmeijer S, Vischer HF, Rosethorne EM, Charlton SJ, Leurs R. Analysis of multiple histamine H₄ receptor compound classes uncovers Gαi protein- and β-arrestin2-biased ligands. **Molecular Pharmacology** **2012**, 82(6)**:** 1174-1182. doi: 10.1124/mol.112.080911

76. Shang P, Rong N, Jiang JJ, Cheng J, Zhang MH, Kang D*, et al.* Structural and signaling mechanisms of TAAR1 enabled preferential agonist design. **Cell** **2023**, 186(24)**:** 5347-5362 e5324. doi: 10.1016/j.cell.2023.10.014

77. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K*, et al.* Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. **Journal of Pharmacology and Experimental Therapeutics** **2010**, 335(3)**:** 572-579. doi: 10.1124/jpet.110.173005

78. Boerrigter G, Soergel DG, Violin JD, Lark MW, Burnett JC, Jr. TRV120027, a novel β-Arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure. **Circulation-Heart Failure** **2012**, 5(5)**:** 627-634. doi: 10.1161/circheartfailure.112.969220

79. Pang PS, Butler J, Collins SP, Cotter G, Davison BA, Ezekowitz JA*, et al.* Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). **European Heart Journal** **2017**, 38(30)**:** 2364-2373. doi: 10.1093/eurheartj/ehx196

80. Parichatikanond W, Duangrat R, Mangmool S. Gαq protein-biased ligand of angiotensin II type 1 receptor mediates myofibroblast differentiation through TGF-β1/ERK axis in human cardiac fibroblasts. **European Journal of Pharmacology** **2023**, 951**:** 175780. doi: 10.1016/j.ejphar.2023.175780

81. Aplin M, Christensen GL, Schneider M, Heydorn A, Gammeltoft S, Kjolbye AL*, et al.* The angiotensin type 1 receptor activates extracellular signal-regulated kinases 1 and 2 by G protein-dependent and -independent pathways in cardiac myocytes and langendorff-perfused hearts. **Basic & Clinical Pharmacology & Toxicology** **2007**, 100(5)**:** 289-295. doi: 10.1111/j.1742-7843.2007.00063.x

82. Wei HJ, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM*, et al.* Independent β-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. **Proceedings of the National Academy of Sciences of the United States of America** **2003**, 100(19)**:** 10782-10787. doi: 10.1073/pnas.1834556100

83. Galandrin S, Denis C, Boularan C, Marie J, M'Kadmi C, Pilette C*, et al.* Cardioprotective angiotensin-(1-7) peptide acts as a natural-biased ligand at the angiotensin II type 1 receptor. **Hypertension** **2016**, 68(6)**:** 1365-1374. doi: 10.1161/HYPERTENSIONAHA.116.08118

84. Namkung Y, LeGouill C, Kumar S, Cao Y, Teixeira LB, Lukasheva V*, et al.* Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. **Science Signaling** **2018**, 11(559). doi: 10.1126/scisignal.aat1631

85. Yang P, Maguire JJ, Davenport AP. Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system. **Trends in Pharmacological Sciences 2015**, 36(9)**:** 560-567. doi: 10.1016/j.tips.2015.06.002

86. Murza A, Sainsily X, Cote J, Bruneau-Cossette L, Besserer-Offroy E, Longpre JM*, et al.* Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. **Organic & Biomolecular Chemistry** **2017**, 15(2)**:** 449-458. doi: 10.1039/c6ob02247b

87. Narayanan S, Vasukuttan V, Rajagopal S, Maitra R, Runyon SP. Identification of potent pyrazole based APELIN receptor (APJ) agonists. **Bioorganic & Medicinal Chemistry** **2020**, 28(4)**:** 115237. doi: 10.1016/j.bmc.2019.115237

88. Ceraudo E, Galanth C, Carpentier E, Banegas-Font I, Schonegge AM, Alvear-Perez R*, et al.* Biased signaling favoring Gi over β-arrestin promoted by an apelin fragment lacking the C-terminal phenylalanine. **The Journal of Biological Chemistry** **2014**, 289(35)**:** 24599-24610. doi: 10.1074/jbc.M113.541698

89. Nyimanu D, Kuc RE, Williams TL, Bednarek M, Ambery P, Jermutus L*, et al.* Apelin-36-[L28A] and apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor. **Peptides** **2019**, 121**:** 170139. doi: 10.1016/j.peptides.2019.170139

90. Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J*, et al.* Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist. **Hypertension** **2015**, 65(4)**:** 834-840. doi: 10.1161/HYPERTENSIONAHA.114.05099

91. Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC*, et al.* Cardiac action of the first G protein biased small molecule apelin agonist. **Biochemical Pharmacology** **2016**, 116**:** 63-72. doi: 10.1016/j.bcp.2016.07.018

92. McAnally D, Siddiquee K, Sharir H, Qi F, Phatak S, Li JL*, et al.* A systematic approach to identify biased agonists of the apelin receptor through high-throughput screening. **SLAS Discovery** **2017**, 22(7)**:** 867-878. doi: 10.1177/2472555217699158

93. Portilla-Martinez A, Ortiz-Flores MA, Meaney E, Villarreal F, Najera N, Ceballos G. (-)-Epicatechin is a biased ligand of apelin receptor. **International Journal of Molecular Sciences** **2022**, 23(16). doi: 10.3390/ijms23168962

94. Wang WW, Ji SY, Zhang W, Zhang J, Cai C, Hu R*, et al.* Structure-based design of non-hypertrophic apelin receptor modulator. **Cell** **2024**, 187(6)**:** 1460-1475 e1420. doi: 10.1016/j.cell.2024.02.004

95. Yadav MK, Maharana J, Yadav R, Saha S, Sarma P, Soni C*, et al.* Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors. **Cell** **2023**, 186(22)**:** 4956-4973 e4921. doi: 10.1016/j.cell.2023.09.020

96. Feng Y, Zhao C, Deng Y, Wang H, Ma L, Liu S*, et al.* Mechanism of activation and biased signaling in complement receptor C5aR1. **Cell Research** **2023**, 33(4)**:** 312-324. doi: 10.1038/s41422-023-00779-2

97. Gorman DM, Li XX, Lee JD, Fung JN, Cui CS, Lee HS*, et al.* Development of potent and selective agonists for complement C5a receptor 1 with In vivo activity. **Journal of Medicinal Chemistry** **2021**, 64(22)**:** 16598-16608. doi: 10.1021/acs.jmedchem.1c01174

98. Maguire JJ. Evidence for biased agonists and antagonists at the endothelin receptors. **Life Sciences** **2016**, 159**:** 30-33. doi: 10.1016/j.lfs.2016.02.069

99. Gabl M, Holdfeldt A, Sundqvist M, Lomei J, Dahlgren C, Forsman H. FPR2 signaling without β-arrestin recruitment alters the functional repertoire of neutrophils. **Biochemical Pharmacology** **2017**, 145**:** 114-122. doi: 10.1016/j.bcp.2017.08.018

100. Mende F, Hundahl C, Plouffe B, Skov LJ, Sivertsen B, Madsen AN*, et al.* Translating biased signaling in the ghrelin receptor system into differential in vivo functions. **Proceedings of the National Academy of Sciences of the United States of America** **2018**, 115(43)**:** E10255-E10264. doi: 10.1073/pnas.1804003115

101. Gross JD, Kim DW, Zhou Y, Jansen D, Slosky LM, Clark NB*, et al.* Discovery of a functionally selective ghrelin receptor (GHSR1a) ligand for modulating brain dopamine. **Proceedings of the National Academy of Sciences of the United States of America** **2022**, 119(10)**:** e2112397119. doi: 10.1073/pnas.2112397119

102. Lensing CJ, Freeman KT, Schnell SM, Speth RC, Zarth AT, Haskell-Luevano C. Developing a biased unmatched bivalent ligand (BUmBL) design strategy to target the GPCR homodimer allosteric signaling (cAMP over β-Arrestin 2 recruitment) within the melanocortin receptors. **Journal of Medicinal Chemistry** **2019**, 62(1)**:** 144-158. doi: 10.1021/acs.jmedchem.8b00238

103. Dai HC, Ji RL, Tao YX. SHU9119 and MBP10 are biased ligands at the human melanocortin-4 receptor. **Biochemical Pharmacology** **2024:** 116325. doi: 10.1016/j.bcp.2024.116325

104. Patruno S, Garrido-Mesa J, Romano M, Perretti M, Montero-Melendez T. Ligand bias and its association with pro-resolving actions of melanocortin drugs. **Frontiers in Pharmacology** **2018**, 9**:** 919. doi: 10.3389/fphar.2018.00919

105. Liao Y, Lu B, Ma Q, Wu G, Lai X, Zang J*, et al.* Human neuropeptide S receptor is activated via a Gαq protein-biased signaling cascade by a human neuropeptide S analog lacking the C-terminal 10 residues. **The Journal of Biological Chemistry** **2016**, 291(14)**:** 7505-7516. doi: 10.1074/jbc.M115.704122

106. Clark SD, Kenakin TP, Gertz S, Hassler C, Gay EA, Langston TL*, et al.* Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation. **Neuropharmacology** **2017**, 118**:** 69-78. doi: 10.1016/j.neuropharm.2017.03.001

107. Kaiser A, Wanka L, Ziffert I, Beck-Sickinger AG. Biased agonists at the human Y 1 receptor lead to prolonged membrane residency and extended receptor G protein interaction. **Cellular and Molecular Life Sciences** **2020**, 77(22)**:** 4675-4691. doi: 10.1007/s00018-019-03432-7

108. Pinkerton AB, Peddibhotla S, Yamamoto F, Slosky LM, Bai Y, Maloney P*, et al.* Discovery of β-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators. **Journal of Medicinal Chemistry** **2019**, 62(17)**:** 8357-8363. doi: 10.1021/acs.jmedchem.9b00340

109. Peddibhotla S, Hedrick MP, Hershberger P, Maloney PR, Li Y, Milewski M*, et al.* Discovery of ML314, a brain penetrant nonpeptidic β‑arrestin biased agonist of the neurotensin NTR1 receptor. **ACS Medicinal Chemistry Letters** **2013**, 4(9)**:** 846-851. doi: 10.1021/ml400176n

110. Gutridge AM, Robins MT, Cassell RJ, Uprety R, Mores KL, Ko MJ*, et al.* G protein-biased kratom-alkaloids and synthetic carfentanil-amide opioids as potential treatments for alcohol use disorder. **British Journal of Pharmacology** **2020**, 177(7)**:** 1497-1513. doi: 10.1111/bph.14913

111. Conibear AE, Asghar J, Hill R, Henderson G, Borbely E, Tekus V*, et al.* A novel G protein-biased agonist at the delta opioid receptor with analgesic efficacy in models of chronic pain. **Journal of Pharmacology and Experimental Therapeutics** **2020**, 372(2)**:** 224-236. doi: 10.1124/jpet.119.258640

112. Chiang T, Sansuk K, van Rijn RM. β-Arrestin 2 dependence of δ opioid receptor agonists is correlated with alcohol intake. **British Journal of Pharmacology** **2016**, 173(2)**:** 332-343. doi: 10.1111/bph.13374

113. Fossler MJ, Schmith V, Greene SA, Lohmer L, Kramer MS, Arscott K*, et al.* A phase I, randomized, single‑blind, placebo‑controlled, single ascending dose study of the safety, tolerability, and pharmacokinetics of subcutaneous and oral TRV250, a G protein-selective delta receptor agonist, in healthy subjects. **CNS Drugs** **2020**, 34(8)**:** 853-865. doi: 10.1007/s40263-020-00738-0

114. Cassell RJ, Mores KL, Zerfas BL, Mahmoud AH, Lill MA, Trader DJ*, et al.* Rubiscolins are naturally occurring G protein-biased delta opioid receptor peptides. **European Neuropsychopharmacology** **2019**, 29(3)**:** 450-456. doi: 10.1016/j.euroneuro.2018.12.013

115. Stanczyk MA, Livingston KE, Chang L, Weinberg ZY, Puthenveedu MA, Traynor JR. The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist. **British Journal of Pharmacology** **2019**, 176(11)**:** 1649-1663. doi: 10.1111/bph.14602

116. Charfi I, Audet N, Tudashki HB, Pineyro G. Identifying ligand-specific signalling within biased responses: focus on δ opioid receptor ligands. **British Journal of Pharmacology** **2015**, 172(2)**:** 435-448. doi: 10.1111/bph.12705

117. Gomes I, Sierra S, Lueptow L, Gupta A, Gouty S, Margolis EB*, et al.* Biased signaling by endogenous opioid peptides. **Proceedings of the National Academy of Sciences of the United States of America** **2020**, 117(21)**:** 11820-11828. doi: 10.1073/pnas.2000712117

118. Schmid CL, Streicher JM, Groer CE, Munro TA, Zhou L, Bohn LM. Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. **The Journal of Biological Chemistry** **2013**, 288(31)**:** 22387-22398. doi: 10.1074/jbc.M113.476234

119. White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK*, et al.* The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. **Journal of Pharmacology and Experimental Therapeutics** **2015**, 352(1)**:** 98-109. doi: 10.1124/jpet.114.216820

120. Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL*, et al.* Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. **Science Signaling** **2016**, 9(456)**:** ra117. doi: 10.1126/scisignal.aai8441

121. Zhou L, Lovell KM, Frankowski KJ, Slauson SR, Phillips AM, Streicher JM*, et al.* Development of functionally selective, small molecule agonists at kappa opioid receptors. **Journal of Biological Chemistry** **2013**, 288(51)**:** 36703-36716. doi: 10.1074/jbc.M113.504381

122. Spetea M, Eans SO, Ganno ML, Lantero A, Mairegger M, Toll L*, et al.* Selective κ receptor partial agonist HS666 produces potent antinociception without inducing aversion after i.c.v. administration in mice. **British Journal of Pharmacology** **2017**, 174(15)**:** 2444-2456. doi: 10.1111/bph.13854

123. Gupta A, Gomes I, Bobeck EN, Fakira AK, Massaro NP, Sharma I*, et al.* Collybolide is a novel biased agonist of κ-opioid receptors with potent antipruritic activity. **Proceedings of the National Academy of Sciences of the United States of America** **2016**, 113(21)**:** 6041-6046. doi: 10.1073/pnas.1521825113

124. Maillet EL, Milon N, Heghinian MD, Fishback J, Schurer SC, Garamszegi N*, et al.* Noribogaine is a G-protein biased k -opioid receptor agonist. **Neuropharmacology** **2015**, 99**:** 675-688. doi: 10.1016/j.neuropharm.2015.08.032

125. Zheng Z, Huang X-P, Mangano TJ, Zuo R, Chen X, Zaidi SA*, et al.* Structure-based discovery of new antagonist and biased agonist chemotypes for the kappa opioid receptor. **Journal of Medicinal Chemistry** **2017**, 60(7)**:** 3070-3081. doi: 10.1021/acs.jmedchem.7b00109

126. Bedini A, Di Cesare Mannelli L, Micheli L, Baiula M, Vaca G, De Marco R*, et al.* Functional selectivity and antinociceptive effects of a novel KOPr agonist. **Frontiers in Pharmacology** **2020**, 11**:** 188. doi: 10.3389/fphar.2020.00188

127. El Daibani A, Paggi JM, Kim K, Laloudakis YD, Popov P, Bernhard SM*, et al.* Molecular mechanism of biased signaling at the kappa opioid receptor. **Nature Communications** **2023**, 14(1)**:** 1338. doi: 10.1038/s41467-023-37041-7

128. Schattauer SS, Kuhar JR, Song A, Chavkin C. Nalfurafine is a G-protein biased agonist having significantly greater bias at the human than rodent form of the kappa opioid receptor. **Cellular Signalling** **2017**, 32**:** 59-65. doi: 10.1016/j.cellsig.2017.01.016

129. Lovell KM, Frankowski KJ, Stahl EL, Slauson SR, Yoo E, Prisinzano TE*, et al.* Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over betaarrestin2 signaling bias. **ACS Chemical Neuroscience** **2015**, 6(8)**:** 1411-1419. doi: 10.1021/acschemneuro.5b00092

130. White KL, Scopton AP, Rives ML, Bikbulatov RV, Polepally PR, Brown PJ*, et al.* Identification of novel functionally selective κ-opioid receptor scaffolds. **Molecular Pharmacology** **2014**, 85(1)**:** 83-90. doi: 10.1124/mol.113.089649

131. DiMattio KM, Ehlert FJ, Liu-Chen LY. Intrinsic relative activities of κ opioid agonists in activating Gα proteins and internalizing receptor: Differences between human and mouse receptors. **European Journal of Pharmacology** **2015**, 761**:** 235-244. doi: 10.1016/j.ejphar.2015.05.054

132. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D, Corder G*, et al.* Structure-based discovery of opioid analgesics with reduced side effects. **Nature** **2016**, 537(7619)**:** 185-190. doi: 10.1038/nature19112

133. DeWire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL, Graczyk TM*, et al.* A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. **Journal of Pharmacology and Experimental Therapeutics** **2013**, 344(3)**:** 708-717. doi: 10.1124/jpet.112.201616

134. Chen XT, Pitis P, Liu G, Yuan C, Gotchev D, Cowan CL*, et al.* Structure-activity relationships and discovery of a G protein biased μ opioid receptor ligand, [(3-methoxythiophen-2-yl)methyl]({2-[(9R)-9-(pyridin-2-yl)-6-oxaspiro-[4.5]decan-9-yl]ethyl})amine (TRV130), for the treatment of acute severe pain. **Journal of Medicinal Chemistry** **2013**, 56(20)**:** 8019-8031. doi: 10.1021/jm4010829

135. Li X, He W, Chen Y, Yang G, Wan H, Zhang L*, et al.* Discovery of SHR9352: A highly potent G protein-biased μ-opioid receptor agonist. **ACS Omega** **2017**, 2(12)**:** 9261-9267. doi: 10.1021/acsomega.7b01452

136. De Neve J, Barlow TMA, Tourwe D, Bihel F, Simonin F, Ballet S. Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors. **Rsc Medicinal Chemistry** **2021**, 12(6)**:** 828-870. doi: 10.1039/d1md00041a

137. Ramos KA, James IE, Skobieranda F, Soergel DG, Ruff D, Fossler MJ. Two-part phase 1 multiple-ascending-dose study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of TRV734 in healthy adults. **Clinical Pharmacology in Drug Development** **2022**, 11(1)**:** 51-62. doi: 10.1002/cpdd.1016

138. Ehrlich AT, Semache M, Gross F, Da Fonte DF, Runtz L, Colley C*, et al.* Biased signaling of the Mu opioid receptor revealed in native neurons. **iScience** **2019**, 14**:** 47-57. doi: 10.1016/j.isci.2019.03.011

139. Faouzi A, Wang H, Zaidi SA, DiBerto JF, Che T, Qu Q*, et al.* Structure-based design of bitopic ligands for the μ-opioid receptor. **Nature** **2023**, 613(7945)**:** 767-774. doi: 10.1038/s41586-022-05588-y

140. Schmid CL, Kennedy NM, Ross NC, Lovell KM, Yue Z, Morgenweck J*, et al.* Bias factor and therapeutic window correlate to predict safer opioid analgesics. **Cell** **2017**, 171(5)**:** 1165-1175 e1113. doi: 10.1016/j.cell.2017.10.035

141. Stahl EL, Schmid CL, Acevedo-Canabal A, Read C, Grim TW, Kennedy NM*, et al.* G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists. **Proceedings of the National Academy of Sciences of the United States of America** **2021**, 118(48)**:** e2102178118. doi: 10.1073/pnas.2102178118

142. Yang Y, Wang Y, Zuo A, Li C, Wang W, Jiang W*, et al.* Synthesis, biological, and structural explorations of a series of mu-opioid receptor (MOR) agonists with high G protein signaling bias. **European Journal of Medicinal Chemistry** **2022**, 228**:** 113986. doi: 10.1016/j.ejmech.2021.113986

143. Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT*, et al.* Optimization of a series of Mu opioid receptor (MOR) agonists with high G protein signaling bias. **Journal of Medicinal Chemistry** **2018**, 61(19)**:** 8895-8907. doi: 10.1021/acs.jmedchem.8b01136

144. Zhang Y, Williams DA, Zaidi SA, Yuan Y, Braithwaite A, Bilsky EJ*, et al.* 17-Cyclopropylmethyl-3,14beta-dihydroxy-4,5alpha-epoxy-6beta-(4'-pyridylcarboxamido)morphinan (NAP) modulating the Mu Opioid receptor in a biased fashion. **Acs Chemical Neuroscience** **2016**, 7(3)**:** 297-304. doi: 10.1021/acschemneuro.5b00245

145. Whistler JL, von Zastrow M. Morphine-activated opioid receptors elude desensitization by β-arrestin. **Proceedings of the National Academy of Sciences of the United States of America** **1998**, 95(17)**:** 9914-9919. doi: 10.1073/pnas.95.17.9914

146. Kruegel AC, Gassaway MM, Kapoor A, Varadi A, Majumdar S, Filizola M*, et al.* Synthetic and receptor signaling explorations of the mitragyna alkaloids: Mitragynine as an atypical molecular framework for opioid receptor modulators. **Journal of the American Chemical Society** **2016**, 138(21)**:** 6754-6764. doi: 10.1021/jacs.6b00360

147. Cai J, Song B, Cai Y, Ma Y, Lam AL, Magiera J*, et al.* Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity. **Bioorganic & Medicinal Chemistry** **2014**, 22(7)**:** 2208-2219. doi: 10.1016/j.bmc.2014.02.015

148. Varadi A, Marrone GF, Palmer TC, Narayan A, Szabo MR, Le Rouzic V*, et al.* Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2. **Journal of Medicinal Chemistry** **2016**, 59(18)**:** 8381-8397. doi: 10.1021/acs.jmedchem.6b00748

149. Le Rouzic V, Narayan A, Hunkle A, Marrone GF, Lu Z, Majumdar S*, et al.* Pharmacological characterization of levorphanol, a G-Protein biased opioid analgesic. **Anesthesia and Analgesia** **2019**, 128(2)**:** 365-373. doi: 10.1213/ANE.0000000000003360

150. Groer CE, Tidgewell K, Moyer RA, Harding WW, Rothman RB, Prisinzano TE*, et al.* An opioid agonist that does not induce mu-opioid receptor-arrestin interactions or receptor internalization. **Molecular Pharmacology** **2007**, 71(2)**:** 549-557. doi: 10.1124/mol.106.028258

151. Crowley RS, Riley AP, Sherwood AM, Groer CE, Shivaperumal N, Biscaia M*, et al.* Synthetic studies of neoclerodane diterpenes from Salvia divinorum: Identification of a potent and centrally acting mu opioid analgesic with reduced abuse liability. **Journal of Medicinal Chemistry** **2016**, 59(24)**:** 11027-11038. doi: 10.1021/acs.jmedchem.6b01235

152. Thompson GL, Lane JR, Coudrat T, Sexton PM, Christopoulos A, Canals M. Systematic analysis of factors influencing observations of biased agonism at the mu-opioid receptor. **Biochemical Pharmacology** **2016**, 113**:** 70-87. doi: 10.1016/j.bcp.2016.05.014

153. Kaserer T, Steinacher T, Kainhofer R, Erli F, Sturm S, Waltenberger B*, et al.* Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists. **Scientific Reports** **2020**, 10(1)**:** 13804. doi: 10.1038/s41598-020-70493-1

154. Piekielna-Ciesielska J, Artali R, Azzam AAH, Lambert DG, Kluczyk A, Gentilucci L*, et al.* Pharmacological characterization of μ-opioid receptor agonists with biased G protein or β-arrestin signaling, and computational study of conformational changes during receptor activation. **Molecules** **2021**, 26(1). doi: 10.3390/molecules26010013

155. Groom S, Blum NK, Conibear AE, Disney A, Hill R, Husbands SM*, et al.* A novel G protein-biased agonist at the mu opioid receptor induces substantial receptor desensitisation through G protein-coupled receptor kinase. **British Journal of Pharmacology** **2023**, 180(7)**:** 943-957. doi: 10.1111/bph.15334

156. Zebala JA, Schuler AD, Kahn SJ, Maeda DY. Desmetramadol is identified as a G-protein biased µ opioid receptor agonist. **Frontiers in Pharmacology** **2019**, 10**:** 1680. doi: 10.3389/fphar.2019.01680

157. Dekan Z, Sianati S, Yousuf A, Sutcliffe KJ, Gillis A, Mallet C*, et al.* A tetrapeptide class of biased analgesics from an Australian fungus targets the µ-opioid receptor. **Proceedings of the National Academy of Sciences of the United States of America** **2019**, 116(44)**:** 22353-22358. doi: 10.1073/pnas.1908662116

158. Ramos-Gonzalez N, Groom S, Sutcliffe KJ, Bancroft S, Bailey CP, Sessions RB*, et al.* Carfentanil is a beta-arrestin-biased agonist at the mu opioid receptor. **British Journal of Pharmacology** **2023**, 180(18)**:** 2341-2360. doi: 10.1111/bph.16084

159. Chang SD, Mascarella SW, Spangler SM, Gurevich VV, Navarro HA, Carroll FI*, et al.* Quantitative signaling and structure-activity analyses demonstrate functional selectivity at the nociceptin/orphanin FQ opioid receptor. **Molecular Pharmacology** **2015**, 88(3)**:** 502-511. doi: 10.1124/mol.115.099150

160. Malfacini D, Ambrosio C, Gro MC, Sbraccia M, Trapella C, Guerrini R*, et al.* Pharmacological profile of nociceptin/orphanin FQ receptors interacting with G-proteins and β-arrestins 2. **PLoS One** **2015**, 10(8)**:** e0132865. doi: 10.1371/journal.pone.0132865

161. Rizzi A, Cerlesi MC, Ruzza C, Malfacini D, Ferrari F, Bianco S*, et al.* Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. **Pharmacology Research & Perspectives** **2016**, 4(4)**:** e00247. doi: 10.1002/prp2.247

162. Chao PK, Chang HF, Chang WT, Yeh TK, Ou LC, Chuang JY*, et al.* BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine. **Neuropharmacology** **2020**, 166**:** 107678. doi: 10.1016/j.neuropharm.2019.107678

163. Hollenberg MD, Mihara K, Polley D, Suen JY, Han A, Fairlie DP*, et al.* Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease. **British Journal of Pharmacology** **2014**, 171(5)**:** 1180-1194. doi: 10.1111/bph.12544

164. Suen JY, Cotterell A, Lohman RJ, Lim J, Han A, Yau MK*, et al.* Pathway-selective antagonism of proteinase activated receptor 2. **British Journal of Pharmacology** **2014**, 171(17)**:** 4112-4124. doi: 10.1111/bph.12757

165. Zhao P, Lieu T, Barlow N, Metcalf M, Veldhuis NA, Jensen DD*, et al.* Cathepsin S causes inflammatory pain via biased agonism of PAR2 and TRPV4. **Journal of Biological Chemistry** **2014**, 289(39)**:** 27215-27234. doi: 10.1074/jbc.M114.599712

166. Kocan M, Sarwar M, Ang SY, Xiao J, Marugan JJ, Hossain MA*, et al.* ML290 is a biased allosteric agonist at the relaxin receptor RXFP1. **Scientific Reports** **2017**, 7(1)**:** 2968. doi: 10.1038/s41598-017-02916-5

167. van der Westhuizen ET, Christopoulos A, Sexton PM, Wade JD, Summers RJ. H2 relaxin is a biased ligand relative to H3 relaxin at the relaxin family peptide receptor 3 (RXFP3). **Molecular Pharmacology** **2010**, 77(5)**:** 759-772. doi: 10.1124/mol.109.061432

168. Harris JA, Faust B, Gondin AB, Damgen MA, Suomivuori CM, Veldhuis NA*, et al.* Selective G protein signaling driven by substance P-neurokinin receptor dynamics. **Nature Chemical Biology** **2022**, 18(1)**:** 109-115. doi: 10.1038/s41589-021-00890-8

169. Brule C, Perzo N, Joubert JE, Sainsily X, Leduc R, Castel H*, et al.* Biased signaling regulates the pleiotropic effects of the urotensin II receptor to modulate its cellular behaviors. **FASEB Journal** **2014**, 28(12)**:** 5148-5162. doi: 10.1096/fj.14-249771

170. Rahmeh R, Damian M, Cottet M, Orcel H, Mendre C, Durroux T*, et al.* Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy. **Proceedings of the National Academy of Sciences of the United States of America** **2012**, 109(17)**:** 6733-6738. doi: 10.1073/pnas.1201093109

171. Duerrauer L, Muratspahic E, Gattringer J, Keov P, Mendel HC, Pfleger KDG*, et al.* I8-arachnotocin-an arthropod-derived G protein-biased ligand of the human vasopressin V(2) receptor. **Scientific Reports** **2019**, 9(1)**:** 19295. doi: 10.1038/s41598-019-55675-w

172. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M*, et al.* The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. **Journal of Biological Chemistry** **2005**, 280(16)**:** 16311-16318. doi: 10.1074/jbc.M409945200

173. Shao Z, Shen Q, Yao B, Mao C, Chen LN, Zhang H*, et al.* Identification and mechanism of G protein-biased ligands for chemokine receptor CCR1. **Nature Chemical Biology** **2022**, 18(3)**:** 264-271. doi: 10.1038/s41589-021-00918-z

174. Corbisier J, Huszagh A, Gales C, Parmentier M, Springael JY. Partial agonist and biased signaling properties of the synthetic enantiomers J113863/UCB35625 at chemokine receptors CCR2 and CCR5. **The Journal of Biological Chemistry** **2017**, 292(2)**:** 575-584. doi: 10.1074/jbc.M116.757559

175. Lorenzen E, Ceraudo E, Berchiche YA, Rico CA, Furstenberg A, Sakmar TP*, et al.* G protein subtype-specific signaling bias in a series of CCR5 chemokine analogs. **Science Signaling** **2018**, 11(552). doi: 10.1126/scisignal.aao6152

176. Boon K, Vanalken N, Szpakowska M, Chevigne A, Schols D, Van Loy T. Systematic assessment of chemokine ligand bias at the human chemokine receptor CXCR2 indicates G protein bias over β-arrestin recruitment and receptor internalization. **Cell Communication and Signaling** **2024**, 22(1)**:** 43. doi: 10.1186/s12964-023-01460-2

177. Watts AO, Scholten DJ, Heitman LH, Vischer HF, Leurs R. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation. **Biochemical and Biophysical Research Communications** **2012**, 419(2)**:** 412-418. doi: 10.1016/j.bbrc.2012.02.036

178. Zheng K, Smith JS, Eiger DS, Warman A, Choi I, Honeycutt CC*, et al.* Biased agonists of the chemokine receptor CXCR3 differentially signal through Gαi:β-arrestin complexes. **Science Signaling** **2022**, 15(726). doi: 10.1126/scisignal.abg5203

179. Milanos L, Brox R, Frank T, Poklukar G, Palmisano R, Waibel R*, et al.* Discovery and characterization of biased allosteric agonists of the chemokine receptor CXCR3. **Journal of Medicinal Chemistry** **2016**, 59(5)**:** 2222-2243. doi: 10.1021/acs.jmedchem.5b01965

180. Quoyer J, Janz JM, Luo J, Ren Y, Armando S, Lukashova V*, et al.* Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. **Proceedings of the National Academy of Sciences of the United States of America** **2013**, 110(52)**:** E5088-5097. doi: 10.1073/pnas.1312515110

181. Mao C, Xiao P, Tao XN, Qin J, He QT, Zhang C*, et al.* Unsaturated bond recognition leads to biased signal in a fatty acid receptor. **Science** **2023**, 380(6640)**:** eadd6220. doi: 10.1126/science.add6220

182. Li A, Yang D, Zhu M, Tsai KC, Xiao KH, Yu X*, et al.* Discovery of novel FFA4 (GPR120) receptor agonists with beta-arrestin2-biased characteristics. **Future Medicinal Chemistry** **2015**, 7(18)**:** 2429-2437. doi: 10.4155/fmc.15.160

183. Galvani S, Sanson M, Blaho VA, Swendeman SL, Conger H, Dahlback B*, et al.* HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. **Science Signaling** **2015**, 8(389)**:** ra79. doi: 10.1126/scisignal.aaa2581

184. Dhar TG, Xiao HY, Xie J, Lehman-McKeeman LD, Wu DR, Dabros M*, et al.* Identification and preclinical pharmacology of BMS-986104: a differentiated S1P1 receptor modulator in clinical trials. **ACS Medicinal Chemistry Letters** **2016**, 7(3)**:** 283-288. doi: 10.1021/acsmedchemlett.5b00448

185. Toyomoto M, Inoue A, Iida K, Denawa M, Kii I, Ngako Kadji FM*, et al.* S1PR3-G12-biased agonist ALESIA targets cancer metabolism and promotes glucose starvation. **Cell Chemical Biology** **2021**, 28(8)**:** 1132-1144 e1139. doi: 10.1016/j.chembiol.2021.01.004

186. Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Biased type 1 cannabinoid receptor signaling influences neuronal viability in a cell culture model of huntington disease. **Molecular Pharmacology** **2016**, 89(3)**:** 364-375. doi: 10.1124/mol.115.101980

187. Breivogel CS, Lambert JM, Gerfin S, Huffman JW, Razdan RK. Sensitivity to Δ9-tetrahydrocannabinol is selectively enhanced in beta-arrestin2-/- mice. **Behavioural Pharmacology** **2008**, 19(4)**:** 298-307. doi: 10.1097/FBP.0b013e328308f1e6

188. Ahn KH, Mahmoud MM, Samala S, Lu D, Kendall DA. Profiling two indole-2-carboxamides for allosteric modulation of the CB1 receptor. **Journal of Neurochemistry** **2013**, 124(5)**:** 584-589. doi: 10.1111/jnc.12115

189. Khurana L, Fu BQ, Duddupudi AL, Liao YH, Immadi SS, Kendall DA*, et al.* Pyrimidinyl biphenylureas: Identification of new lead compounds as allosteric modulators of the cannabinoid receptor CB1. **Journal of Medicinal Chemistry** **2017**, 60(3)**:** 1089-1104. doi: 10.1021/acs.jmedchem.6b01448

190. Wouters E, Walraed J, Robertson MJ, Meyrath M, Szpakowska M, Chevigne A*, et al.* Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds. **ACS Pharmacology & Translational Science** **2020**, 3(2)**:** 285-295. doi: 10.1021/acsptsci.9b00069

191. Shen S, Wu C, Lin G, Yang X, Zhou Y, Zhao C*, et al.* Structure-based identification of a G protein-biased allosteric modulator of cannabinoid receptor CB1. **Proceedings of the National Academy of Sciences of the United States of America** **2024**, 121(24)**:** e2321532121. doi: 10.1073/pnas.2321532121

192. Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A*, et al.* Discovery of a biased allosteric modulator for cannabinoid 1 receptor: Preclinical anti-glaucoma efficacy. **Journal of Medicinal Chemistry** **2021**, 64(12)**:** 8104-8126. doi: 10.1021/acs.jmedchem.1c00040

193. Dhopeshwarkar A, Mackie K. Functional selectivity of CB2 cannabinoid receptor ligands at a canonical and noncanonical pathway. **The Journal of Pharmacology and Experimental Therapeutics** **2016**, 358(2)**:** 342-351. doi: 10.1124/jpet.116.232561

194. Oyagawa CRM, de la Harpe SM, Saroz Y, Glass M, Vernall AJ, Grimsey NL. Cannabinoid receptor 2 signalling bias elicited by 2,4,6-trisubstituted 1,3,5-triazines. **Frontiers in Pharmacology** **2018**, 9**:** 1202. doi: 10.3389/fphar.2018.01202

195. Ogawa S, Watanabe T, Sugimoto I, Moriyuki K, Goto Y, Yamane S*, et al.* Discovery of G protein-biased EP2 receptor agonists. **ACS Medicinal Chemistry Letters** **2016**, 7(3)**:** 306-311. doi: 10.1021/acsmedchemlett.5b00455

196. Leduc M, Breton B, Gales C, Le Gouill C, Bouvier M, Chemtob S*, et al.* Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands. **The Journal of Pharmacology and Experimental Therapeutics** **2009**, 331(1)**:** 297-307. doi: 10.1124/jpet.109.156398

197. Valant C, May LT, Aurelio L, Chuo CH, White PJ, Baltos JA*, et al.* Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. **Proceedings of the National Academy of Sciences of the United States of America** **2014**, 111(12)**:** 4614-4619. doi: 10.1073/pnas.1320962111

198. Aurelio L, Baltos JA, Ford L, Nguyen ATN, Jorg M, Devine SM*, et al.* A structure-activity relationship study of bitopic N6-substituted adenosine derivatives as biased adenosine A 1 receptor agonists. **Journal of Medicinal Chemistry** **2018**, 61(5)**:** 2087-2103. doi: 10.1021/acs.jmedchem.8b00047

199. Baltos JA, Gregory KJ, White PJ, Sexton PM, Christopoulos A, May LT. Quantification of adenosine A(1) receptor biased agonism: Implications for drug discovery. **Biochemical Pharmacology** **2016**, 99**:** 101-112. doi: 10.1016/j.bcp.2015.11.013

200. Valant C, Aurelio L, Devine SM, Ashton TD, White JM, Sexton PM*, et al.* Synthesis and characterization of novel 2-amino-3-benzoylthiophene derivatives as biased allosteric agonists and modulators of the adenosine A(1) receptor. **Journal of Medicinal Chemistry** **2012**, 55(5)**:** 2367-2375. doi: 10.1021/jm201600e

201. Langemeijer EV, Verzijl D, Dekker SJ, Ijzerman AP. Functional selectivity of adenosine A1 receptor ligands? **Purinergic Signal** **2013**, 9(1)**:** 91-100. doi: 10.1007/s11302-012-9334-3

202. Wall MJ, Hill E, Huckstepp R, Barkan K, Deganutti G, Leuenberger M*, et al.* Selective activation of Gαob by an adenosine A1 receptor agonist elicits analgesia without cardiorespiratory depression. **Nature communications** **2022**, 13(1)**:** 4150. doi: 10.1038/s41467-022-31652-2

203. Ma L, Yang F, Wu X, Mao C, Guo L, Miao T*, et al.* Structural basis and molecular mechanism of biased GPBAR signaling in regulating NSCLC cell growth via YAP activity. **Proceedings of the National Academy of Sciences of the United States of America** **2022**, 119(29)**:** e2117054119. doi: 10.1073/pnas.2117054119

204. Zhao C, Wang H, Liu Y, Cheng L, Wang B, Tian X*, et al.* Biased allosteric activation of ketone body receptor HCAR2 suppresses inflammation. **Molecular Cell** **2023**, 83(17)**:** 3171-3187 e3177. doi: 10.1016/j.molcel.2023.07.030

205. Walters RW, Shukla AK, Kovacs JJ, Violin JD, DeWire SM, Lam CM*, et al.* beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. **Journal of Clinical Investigation** **2009**, 119(5)**:** 1312-1321. doi: 10.1172/JCI36806

206. Lai E, Waters MG, Tata JR, Radziszewski W, Perevozskaya I, Zheng W*, et al.* Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. **Journal of Clinical Lipidology** **2008**, 2(5)**:** 375-383. doi: 10.1016/j.jacl.2008.08.445

207. Yadav MK, Sarma P, Maharana J, Ganguly M, Mishra S, Zaidi N*, et al.* Structure-guided engineering of biased-agonism in the human niacin receptor via single amino acid substitution. **Nature communications** **2024**, 15(1)**:** 1939. doi: 10.1038/s41467-024-46239-2

208. Lucy D, Purvis GSD, Zeboudj L, Chatzopoulou M, Recio C, Bataille CJR*, et al.* A biased agonist at immunometabolic receptor GPR84 causes distinct functional effects in macrophages. **Acs Chemical Biology** **2019**, 14(9)**:** 2055-2064. doi: 10.1021/acschembio.9b00533

209. Wang P, Raja A, Luscombe VB, Bataille CJR, Lucy D, Rogga VV*, et al.* Development of highly potent, G-protein pathway biased, selective, and orally bioavailable GPR84 agonists. **Journal of Medicinal Chemistry** **2024**, 67(1)**:** 110-137. doi: 10.1021/acs.jmedchem.3c00951

210. Roy S, Ganguly A, Haque M, Ali H. Angiogenic host defense peptide AG-30/5C and bradykinin B2 receptor antagonist icatibant are G protein biased agonists for MRGPRX2 in mast cells. **The Journal of Immunology** **2019**, 202(4)**:** 1229-1238. doi: 10.4049/jimmunol.1801227